Our observations suggest that the therapeutic effects of GRIM19 ameliorate obesity by means of BAT induction and Th17 cell suppression through pSTAT3 inhibition. The gene discussed is NDUFA13; the disease is obesity due to melanocortin 4 receptor deficiency.